Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
Recruiting · NCT02478892 · Observational (researchers observe without assigning treatment) · Lead sponsor: Abramson Cancer Center at Penn Medicine
View the official record on ClinicalTrials.gov →Interventions studied
Blood sample collection for researchCollection of data from endoscopic ultrasound or MRI/MRCP of the abdomen
What this trial is about
The study is a prospective, observational study evaluating the utility of endoscopic ultrasound or MRI for the identification of preneoplastic and neoplastic pancreatic lesions in patients at high risk for pancreatic cancer, specifically those with BRCA1/2, ATM, or PALB2 mutations.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age \>= 18
- Documented germline pathogenic or likely pathogenic BRCA1, BRCA2, ATM, or PALB2 mutation
- If no history of PDAC in a first or second degree relative, age \>= 50
- If there is a history of PDAC in a first or second degree relative, minimum age of eligibility is 10 years younger than the age of onset of the youngest relative with pancreatic cancer
Exclusion criteria
- Pregnancy
Where it is running
1 location listed across 1 US state.
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia, Pennsylvania, United States